



2014-12-30

**PRESS RELEASE**

**Oasmia receives a new MSEK 20 bank loan**

UPPSALA, SWEDEN – December 30, 2014. Oasmia Pharmaceutical AB (publ) announced today that it has received a new MSEK 20 bank loan. The loan replaces a previous MSEK 40 bank loan which is due on December 30, 2014.

**For more information, please contact:**

Anders Lundin, CFO

Mobile: +46 70 209 63 00

E-mail: anders.lundin@oasmia.com

**About Oasmia Pharmaceutical AB**

Oasmia Pharmaceutical AB develops a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well-established cytostatics which, compared to current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. Product development is based on in-house research within nanotechnology and proprietary patents. Oasmia Pharmaceutical AB's shares, ISIN SE0000722365, are listed on NASDAQ Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX).

---

Information is also available at [www.oasmia.com](http://www.oasmia.com), [www.nasdaqomxnordic.com](http://www.nasdaqomxnordic.com), [www.boerse-frankfurt.de](http://www.boerse-frankfurt.de) and [twitter.com/oasmia](https://twitter.com/oasmia)

*"Oasmia is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 8.30 CET on December 30, 2014."*